Welcome: Guest | Site Use Options | Register | Login |

Talon Therapeutics

Talon Therapeutics

Profile last edited on: 5/21/2014
2207 Bridgepointe Parkway, Suite 250
San Mateo, CA 94404
  (650) 588-6404
  info@talontx.com
  www.talontx.com
Business Identifier: NO Business Identifier is currently available for this company.
Public Profile:
Previously known as Hana Biosciences, Inc. Talon Therapeutics, Inc. changed its name in December 2010. In July 2013, Talon was acquired by Spectrum Pharmaceuticals and ceased trading. Talon is a biopharmaceutical company focused on cancer care. Its lead product candidate, Marqibo (vincristine sulfate liposomes injection), is a targeted Optisome encapsulated formulation product candidate, which is in the development for the treatment of acute lymphoblastic leukemia and lymphomas. TIn addition to Marqibo (vincCRIStine sulfate LIPOSOME injection) which received accelerated approval from the US FDA for the treatment of Philadelphia chromosome negative adult acute lymphoblastic leukemia (ALL) patients in second or greater relapse or whose disease has progressed following two or more prior lines of anti-leukemia therapy, Talon has additional pipeline opportunities some of which like Marqibo, have the potential to improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity. The company?s product candidates also include Menadione Topical Lotion, a supportive care product candidate for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, a type of anti-cancer agent used in the treatment of cell lung cancer, pancreatic, colorectal, breast, and head and neck cancer; and Brakiva (topotecan liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of solid tumors, including small cell lung cancer and ovarian cancer. In addition, its development stage product consists of Alocrest (vinorelbine liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of solid tumors, such as non-small-cell lung cancer. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. In addition to Marqibo (vincCRIStine sulfate LIPOSOME injection) which received accelerated approval from the US FDA for the treatment of Philadelphia chromosome negative adult acute lymphoblastic leukemia (ALL) patients in second or greater relapse or whose disease has progressed following two or more prior lines of anti-leukemia therapy, Talon has additional pipeline opportunities some of which like Marqibo, have the potential to improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity.

 Synopsis: Awardee Business Condition
Year Founded First SBIR Year Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol :
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Development of PT523 for the treatment of lung cancer

Unlock access

To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account

Smart Office Options

WikiProfile

Is this YOUR Company?

Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached

Do you know about this Awardees?

Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920

  support@inknowvation.com